By Elsa Ohlen
Hims & Hers stock jumped after the telehealth company that has built a business around selling copycat weight-loss drugs announced a deal with Ozempic-maker Novo Nordisk.
Hims & Hers shares soared 45% to $41.20 in premarket trading.
Novo Nordisk, the maker of Wegovy, its brand for weight-loss, and Ozempic for diabetes, announced a collaboration with Hims & Hers to make obesity treatments more affordable for Americans, the companies said in a joint statement Tuesday.
Novo's American-listed shares rose 3.4% $64.75.
Write to Elsa Ohlen at elsa.ohlen@barrons.com
This is breaking news. Check back for more analysis soon.
This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
April 29, 2025 08:07 ET (12:07 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.